Development Status
For information about the science behind the creation of EVade™ RNase QBI-139 click here.
In September 2006, QBI-139 was selected as a lead
candidate. Large scale production began in early 2007, and toxicology
studies have been completed. The Food and Drug Administration
(FDA) cleared the Investigational New Drug (IND) application,
allowing a Phase 1 clinical trial to begin in early 2009.
In selecting the lead candidate, over thirty EVade™
RNases were manufactured and tested in vivo against
a variety of cancers. QBI-139 was selected because of its broad
efficacy and excellent safety profile. QBI-139 causes significant
tumor growth inhibition in pancreatic, prostate, non-small cell
lung, and ovarian cancers. |
